What Changed
Price Move History
- Daily moves over 5%
- 66 252 sessions, November 13, 2025 to November 13, 2026
- Largest daily move
- -23% close of November 14, 2025
- 1-year change
- +6.7% closing prices, November 13, 2025 to November 13, 2026
- 1-month change
- -9.6% closing prices, October 13, 2026 to November 13, 2026
Company Description
RenovoRx, Inc. (Nasdaq: RNXT) is a life sciences company focused on developing targeted oncology therapies and commercializing RenovoCath®, a U.S. Food and Drug Administration (FDA)-cleared local drug-delivery device. The company’s work centers on high unmet medical needs in cancer, using its patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform to deliver therapeutic agents near the tumor site while potentially reducing the toxicities associated with systemic intravenous chemotherapy.
Core business and therapy platform
RenovoRx’s business combines elements of pharmaceutical preparation manufacturing and medical device commercialization. According to the company’s descriptions in multiple press releases, its patented TAMP therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor. This approach is intended to limit systemic exposure and may help minimize side effects compared with standard systemic intravenous therapy.
The TAMP platform is enabled by RenovoCath, an FDA-cleared, local drug-delivery device. Based on its FDA clearance, RenovoCath is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. It is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.
RenovoCath® device and stand-alone commercialization
RenovoRx is actively commercializing RenovoCath as a stand-alone targeted drug-delivery device. Company disclosures state that RenovoRx has received commercial purchase orders for RenovoCath and is expanding the number of medical institutions initiating orders, including National Cancer Institute-designated centers and community hospitals. Adoption of RenovoCath is described as growing among both new and returning customers, reflecting clinical interest in localized, targeted treatment enabled by the TAMP platform.
The company reports that RenovoCath is used in patient procedures at multiple cancer centers and that repeat purchase orders have been placed by several institutions. RenovoRx has also discussed building a commercial organization, including sales and market development roles, to support broader use of RenovoCath across a domestic network of academic institutions, NCI-designated cancer centers, and high-volume community hospitals.
Drug–device combination candidate (IAG) and TIGeR‑PaC trial
In addition to its cleared device, RenovoRx is evaluating a novel drug–device combination oncology product candidate: intra-arterial gemcitabine delivered via RenovoCath, referred to as IAG. This combination product uses the TAMP therapy platform and is being studied in the ongoing Phase III TIGeR‑PaC clinical trial for patients with locally advanced pancreatic cancer (LAPC). Company communications describe TIGeR‑PaC as a randomized, multi-center trial designed to evaluate intra-arterial administration of gemcitabine using RenovoCath.
IAG is being evaluated by the Center for Drug Evaluation and Research under a U.S. investigational new drug application regulated by the FDA’s 21 CFR 312 pathway. RenovoRx notes that this combination product candidate is currently under investigation and has not been approved for commercial sale. The company also discloses that RenovoCath with gemcitabine has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which would provide seven years of market exclusivity upon new drug application approval by the FDA.
Clinical evidence and scientific rationale
RenovoRx highlights pharmacokinetic (PK) and pharmacodynamic data from a sub‑study of the TIGeR‑PaC trial comparing intra-arterial gemcitabine delivered via TAMP and RenovoCath (IAG) with standard intravenous gemcitabine. According to an abstract presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), TAMP and IAG resulted in reduced systemic levels of gemcitabine and increased levels of its inactive metabolite compared with intravenous administration. A direct correlation was observed between increased metabolite levels and reduced CA 19‑9, a biomarker commonly used to assess potential chemotherapy response.
The company states that by decreasing systemic levels of gemcitabine through limited systemic exposure and rapid conversion to an inactive metabolite, this delivery approach may both increase local drug potency and reduce negative side effects common in pancreatic cancer treatment. These findings are presented by RenovoRx as supportive evidence for the scientific basis of the TAMP platform’s localized approach to targeted chemotherapeutic delivery.
Post‑marketing registry and investigator‑initiated studies
Beyond the TIGeR‑PaC trial, RenovoRx has initiated a post‑marketing observational registry study designed to collect real‑world data on the safety and survival outcomes of patients with solid tumors treated using RenovoCath. Company updates describe this registry as generating real‑world evidence on the use of RenovoCath across solid tumors, with procedures initiated at multiple cancer centers.
RenovoRx also reports supporting capital‑efficient, investigator‑initiated trials in borderline resectable and oligometastatic or metastatic pancreatic cancer. These studies are intended to provide additional data that may further expand the potential clinical utility of the TAMP therapy platform and RenovoCath-enabled treatments.
Commercial and capital strategy
RenovoRx’s disclosures indicate that the company is in the early stages of commercializing its TAMP technology and RenovoCath as a stand‑alone device and has begun generating revenue from device sales. The company has discussed expanding its customer base, fulfilling repeat orders, and exploring additional revenue‑generating activity, either independently or in collaboration with a medical device commercial partner.
From a capital markets perspective, RenovoRx has filed shelf registration statements on Form S‑3 and, according to an 8‑K filed in November 2025, entered into a Capital on Demand™ Sales Agreement with a sales agent. This agreement allows the company to issue and sell shares of common stock from time to time in at‑the‑market offerings or negotiated transactions, providing a mechanism for potential future financing subject to market conditions and company decisions.
Scientific and advisory expertise
The company has announced the expansion of its Scientific Advisory Board (SAB) with recognized experts in pancreatic cancer and interventional oncology. These include a UCLA pancreatic disease surgeon and an interventional oncologist from Gustave Roussy Cancer Centre and University Paris‑Saclay. RenovoRx states that these advisors contribute expertise in surgical oncology, translational oncology research, locoregional cancer therapies, intra‑arterial chemotherapy, and targeted drug delivery, which the company views as directly relevant to the continued development of its TAMP platform and RenovoCath-enabled therapies.
Mission and therapeutic focus
Across its public communications, RenovoRx describes its mission as transforming the lives of cancer patients by providing approaches that enable targeted delivery of diagnostic and therapeutic agents. Its work is concentrated on high unmet medical needs, particularly in pancreatic cancer and other solid tumors where localized, arterial drug delivery may offer a different risk–benefit profile compared with conventional systemic chemotherapy.
Stock Performance
RenovoRx (RNXT) closed at $1.04 on November 13, 2026. Over the past 12 months, the price has gained 6.7%.
RNXT Metrics & Rankings
Price returns through November 13, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
RenovoRx has 10 recent news articles. Of the recent coverage, 6 articles coincided with positive price movement and 3 with negative movement. Key topics include earnings date, earnings. View all RNXT news →
SEC Filings
RenovoRx has filed 10 recent SEC filings, including 5 Form 4, 2 Form 8-K, 1 Form SCHEDULE 13G/A, 1 Form 10-Q. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all RNXT SEC filings →
Financial Highlights
RenovoRx generated $1.1M in revenue in FY2025, retaining a 70.9% gross margin, operating income reached -$12.5M, and net income was -$11.2M. Diluted earnings per share stood at -$0.32. The company generated -$11.0M in operating cash flow. The current ratio was 4.02, measuring current assets divided by current liabilities.
Upcoming Events
TIGeR-PaC final data expected
Pivotal trial final data
TIGeR-PaC topline results
Final trial data readout
TIGeR-PaC full data readout
TIGeR-PaC Completion
TIGeR‑PaC completion
TIGeR-PaC trial completion
TIGeR-PaC final data anticipated
TIGeR-PaC Final Data
Final data readout window
TIGeR-PaC final readout
TIGeR-PaC final data release
TIGeR-PaC initial data
TIGeR-PaC Topline Data
Topline data release
RenovoRx has 17 upcoming scheduled events. The next event, "TIGeR-PaC final data expected", is expected in 2027. Investors can track these dates to stay informed about potential catalysts that may affect the RNXT stock price.
Short Interest History
Short interest in RenovoRx (RNXT) currently stands at 998.0 thousand shares, up 15.4% from the previous reporting period, representing 2.3% of the float. Since November 2025, short interest has increased by 47.6%.
Days to Cover History
Days to cover for RenovoRx (RNXT) currently stands at 3.5 days, up 114% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 134%. Across the settlements charted above, it has ranged from 1.0 to 3.5 days.
RNXT Company Profile & Sector Positioning
RenovoRx (RNXT) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing RNXT often look at related companies in the same sector, including Rein Therapeutics, Inc. (RNTX), Pliant Therapeutics, Inc. (PLRX), Oncolytics Biotech, Inc. (ONCY), Verrica Pharmaceuticals Inc. (VRCA), and MiNK Therapeutics, Inc. (INKT). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate RNXT's relative position within its industry.